Diagnos Inc. TSXV-ADK OTCQB: DGNOF a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of an exclusive distribution agreement with Diagnos Europe GmbH (“Diagnos Europe”), a new partner for DIAGNOS to tackle the strategically important DACH countries in the European market (Germany, Austria, Switzerland) and the surrounding countries Poland, Luxembourg and Liechtenstein in order to prepare a successful market entry for the Company’s products and services in Central Europe, a crucial territory for DIAGNOS with a significant market potential in access of more than 140 million people.
DACH is an abbreviation and D stands for Deutschland (Germany), A, Austria, and CH, Confoederatio Helvetica, (Switzerland). Therefore, it refers to the mostly German-speaking center of Europe. The DACH economy is one of the most stable in the entire world since the end of World War II and it is by far the largest and most promising market for IT and AI in Europe. Diagnos Europe is fully specialized on go-to-market strategies and services in the DACH countries and have developed for DIAGNOS a variety of market entry strategies offering the Company a practical and effective launch pad into the DACH market.
Just as the DACH region has become established as Europe’s most important region for the optical market, DIAGNOS will be benefiting from the forthcoming market entry developments and has in addition that long tapping into European potential. The German market, in particular, plays a leading role in the optical industry and thus also for the Company and Diagnos Europe in terms of preparing the implementation of specific sales activities. Alongside the French market, which DIAGNOS is also targeting at the same time, the German-speaking market is the most important in Europe and also the most interesting for the company as a result of its stable growth rates over the past several years. For 2019, the German optical industry was able to record its most successful financial year in a decade, far outperforming other European markets (total sales compared to 2018 were up by 5.4% at EUR 4.7 billion; 2019 thus exceeding all expectations and a continuation of the growth trend that has persisted since 2011. Opticians and optometrists have continuously been able to look forward to a further increase in turnover, which rose to almost EUR 6.5 billion in 2019 and even more in 2020).
In a world where companies toss the term ‘artificial intelligence’ around whenever the office intern figures out how to get a spreadsheet pie chart to update automatically, it’s nice to see a company utilizing actual AI and machine learning in a manner that involves actual intelligence and learning.
Diagnos (ADK.V) is a health tech deal that scans your eye for evidence of health issues, using AI to deliver fast, inexpensive detection that can be used to scan an entire population.
Click Link for Article: Diagnos Uses AI and Telemedicine to Scan Your Eye for Health Issues in 16 Countries
Aether Catalyst Solutions, Inc. (CSE: ATHR) (“ATHR” or the “Company”), is pleased to announce that the City of Burnaby is working together with Aether on the Urban Small Motors Emissions Abatement Project to evaluate Aether’s emissions abatement technology on select pieces of their equipment employing small motors,
Small motors contribute significantly to urban air pollution: “Today, operating the best-selling commercial lawn mower for one hour emits as much smog-forming pollution as driving the best-selling 2017 passenger car, a Toyota Camry, about 300 miles – approximately the distance from Los Angeles to Las Vegas. ” (California Air Resource Board [arb.ca.gov] Small Engines in California Fact Sheet). Currently, emissions from these small motors are not subject to any emissions abatement technology. Thus, these machines are responsible for considerable volumes of urban air pollution, causing significant amounts of smog, and greenhouse gas emissions.
The common argument used to justify current emission requirements for small motors has been the cost of precious metal-based catalytic converters being too high for consumers. However, with Aether’s low- cost emission reduction technology, the cost argument will no longer be valid.
Under the terms of the MOU entered into between Aether and the City of Burnaby, the parties will cooperate to select appropriate pieces of equipment on which to install Aether’s catalysts, and Aether will utilize the data generated to further optimize its small motors catalysts. Overall, the project will eva
luate the use of Aether’s catalysts as an effective emissions abatement solution for the City of Burnaby’s municipal equipment.
Taylor Procyk, Chief Operating Officer of Aether commented “We are thrilled to begin this project with the City of Burnaby. This is the first step to show how we can contribute to building a cleaner and healthier city for our friends and family.”
“The City of Burnaby is committed to transitioning to zero-emission vehicles and equipment as part of its overall commitment to becoming carbon neutral by 2050, and this project with a local Burnaby company is an opportunity to reduce carbon emissions within existing equipment until they are replaced with zero-emission alternatives,” said Burnaby City Councillor Joe Keithley.
ABOUT THE CITY OF BURNABY:
The City of Burnaby is a vibrant city at the geographic centre of Metro Vancouver. It has an amazing natural environment, a strong cultural mosaic and thriving town centres. To meet the aggressive carbon reduction targets established by Burnaby City Council, a framework called This is Climate Action has been developed to guide how the City will put into action its commitment to be “carbon neutral” (no longer contributing to the carbon emissions that accelerate climate change) by 2050.
ABOUT THE COMPANY:
Aether Catalyst Solutions, Inc. is focused on providing an order of magnitude cost reduction in automotive catalytic converter catalyst, while meeting, or exceeding government emission standards. Aether is working to quickly advance its technology through rapid screening of new materials directed at enhancing end of life conversion levels after accelerated aging. While Aether’s primary focus has been automotive applications, the company is also developing catalysts to address small motors emissions – a significant contributor to urban air pollution.
FOR FURTHER INFORMATION PLEASE CONTACT:
Aether Catalyst Solutions, Inc.
Tel: 604 690-3797
Diagnos Inc. $ADK and the 3rd Largest #optical Retailer in Costa Rica Piloting CARA and its #telemedicine #technology
Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a contract with Óptica Central, the third largest optical chain store in Costa Rica for implementation of CARA across Costa Rica.
“Óptica Central, in collaboration with Aselcom, DIAGNOS’ distributor, are pleased to start screening the population across our optical stores by providing DIAGNOS’ proven AI solution for early detection of eye illnesses, such as Diabetic Retinopathy, as well as preventing blindness caused by diabetes. There is no doubt that DIAGNOS’ experience in Costa Rica, and in other Latin American countries, has been at the forefront in proving its service with their remarkable technology,” said Mr. Jefrey Salas, CEO of Óptica Central.
“At DIAGNOS we have made our mark in different parts of the world, in collaboration with our partners and different stakeholders, where our AI technology and experience for serving patients has set the standard. We know that Diabetic Retinopathy has become the main cause of blindness worldwide occurring in patients aged 20-64 years. Costa Rica is no different from other countries, with almost 15% of its population over 20 having diabetes, with less than 11% diagnosed. At least 35% have been identified with Diabetic Retinopathy within the diabetic population and 10% are in jeopardy of having severe retinopathy that will affect their vision. Our technology is helping now, through Óptica Central, to fill this gap,” said Mr. Andre Larente, President of DIAGNOS.
About Óptica Central
Founded in July 1983, Óptica Central, located in Alajuela, has become a pioneer in the visual health service offering optics and optometry services. Since its inception, it has been contributing to the visual health of the population with affordable prices and a variety of products such as: Specialties Medical Center, 8 Service Centers / Opticians in the metropolitan area, with more than 40 stores located in national territory of Costa Rica.
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224
Expanding globally in the AI image based diagnosis sector, Diagnos is actively commercializing their CARA technology.
Diagnos TSXV-ADK is an AI health care company using non-invasive scanning technology done through the eyeball to detect retinal diabetes and hypertension. They are FDA approved, ISO certified and Health Canada approved.